Department of Neurosurgery, Lou and Jean Malnati Brain Tumor Institute, Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
PECEM, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City 04360, Mexico.
Int J Mol Sci. 2021 Dec 13;22(24):13382. doi: 10.3390/ijms222413382.
Glioblastomas (GBMs) are complex ecosystems composed of highly multifaceted tumor and myeloid cells capable of responding to different environmental pressures, including therapies. Recent studies have uncovered the diverse phenotypical identities of brain-populating myeloid cells. Differences in the immune proportions and phenotypes within tumors seem to be dictated by molecular features of glioma cells. Furthermore, increasing evidence underscores the significance of interactions between myeloid cells and glioma cells that allow them to evolve in a synergistic fashion to sustain tumor growth. In this review, we revisit the current understanding of glioma-infiltrating myeloid cells and their dialogue with tumor cells in consideration of their increasing recognition in response and resistance to immunotherapies as well as the immune impact of the current chemoradiotherapy used to treat gliomas.
胶质母细胞瘤(GBM)是由高度多样化的肿瘤细胞和髓系细胞组成的复杂生态系统,能够对不同的环境压力(包括治疗)作出反应。最近的研究揭示了在大脑中存在的髓系细胞的不同表型特征。肿瘤内免疫比例和表型的差异似乎是由胶质瘤细胞的分子特征决定的。此外,越来越多的证据强调了髓系细胞与胶质瘤细胞之间相互作用的重要性,这种相互作用使它们能够以协同的方式进化,以维持肿瘤的生长。在这篇综述中,我们重新审视了浸润性胶质母细胞瘤的髓系细胞及其与肿瘤细胞的对话,考虑到它们在免疫治疗的反应和耐药性方面的日益认识,以及目前用于治疗胶质母细胞瘤的放化疗的免疫影响。